SEC Charges Cassava Sciences Over Manipulated Alzheimer's Trial …
WEB3 days ago · Alzheimer’s drug developer Cassava Sciences Inc (NASDAQ:SAVA), its founder Remi Barbier, and former Senior VP of Neuroscience Lindsay Burns have agreed to pay over $40 million to resolve SEC ...
Cassava to Pay $40 Million to SEC Over Alzheimer’s Drug Claims
WEB3 days ago · Drugmaker Cassava Sciences Inc. and two former executives agreed to pay more than $40 million to resolve US Securities and Exchange Commission claims they misled the public about the success of an Alzheimer’s drug trial.. Cassava published results in 2020 based on hand-selected data that showed patients’ memories improved, though …
Cassava Sciences and former execs agree to SEC fines | STAT
WEB3 days ago · Sept. 26, 2024. West Coast Biotech & Life Sciences Reporter. Facing charges from the Securities and Exchange Commission for misleading claims related to a controversial Alzheimer’s drug ...
Cassava Sciences Resolves SEC Investigation - GlobeNewswire
WEB3 days ago · Follow. AUSTIN, Texas, Sept. 26, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (“Cassava” or the “Company”) (Nasdaq: SAVA), a biotechnology company focused on Alzheimer’s disease ...
Cassava to Pay $40 Million to SEC Over Alzheimer’s Drug Claims
WEB3 days ago · September 26, 2024 at 7:11 PM EDT. Save. Drugmaker Cassava Sciences Inc.and two former executives agreed to pay more than $40 million to resolve US Securities and Exchange Commission claims they ...
Cassava Sciences, Inc. (SAVA) - Yahoo Finance
WEBGet the latest Cassava Sciences, Inc. (SAVA) stock news and headlines to help you in your trading and investing decisions.
PRESS RELEASES - Cassava Sciences, Inc.
WEBJun 28, 2024 · Cassava Sciences Mourns the Death of Board Member Sanford “Sandy” Robertson. AUSTIN, Texas , Aug. 05, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA) today reflected on the passing …
Cassava Sciences Announces Completion of an Interim Safety
WEB6 days ago · --Cassava Sciences, Inc., a biotechnology company focused on Alzheimer’ s disease, today announced the completion of a third interim safety review of simufilam in on-going Phase 3 clinical ...
Cassava Sciences Announces Science Publication That Confirms …
WEBSep 11, 2023 · Cassava Sciences is evaluating simufilam oral tablets for Alzheimer’s disease dementia in two global Phase 3 clinical studies. These are randomized, double-blind, placebo-controlled trials.
Cassava Sciences Completes Enrollment for Pivotal Phase 3 …
WEBAUSTIN, Texas, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company, today announced the completion of patient enrollment in a pair of Phase 3 trials to evaluate the safety and efficacy of oral simufilam versus placebo in Alzheimer's disease dementia.
- Some results have been removed